Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy
Source abstract
Abstract
Abstract Great success in immunotherapy has revolutionized clinical cancer treatments. However, the response rate and overall survival rate remain unsatisfactory. As one of the immunological hallmarks of cancer, myeloid-derived suppressor cells (MDSCs) induce strong immunosuppression, which leads to great hindrance for immunotherapy of cancer. Thus, MDSCs have been explored as an important immunotherapeutic target to enhance anticancer responses. Nanomedicines have been developed to target MDSCs to improve the immunotherapeutic efficacy owing to their ability of reversing immunosuppressive tumors into immunoresponsive ones. In this review, we describe the function of MDSCs in the tumor microenvironment and the immunosuppressive pathways that inhibit T cell functions. Additionally, recent developments in various nanoparticulate platforms, including nanocapsules, micelles, liposomes, mineralized/metallic nanoparticles and hydrogels, affecting through different pathways and functions of MDSCs as immunomodulatory agents are discussed and highlighted. These nanomedicines have been demonstrated with improved therapeutic efficacies by modulating MDSCs, and they have great potential of translation to clinical application in cancer nano-immunotherapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune cells in cancer · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Tertiary lymphoid structures in the era of cancer immunotherapy10.1038/s41568-019-0144-6 ↗
2. The immune contexture in cancer prognosis and treatment10.1038/nrclinonc.2017.101 ↗
3. Harnessing cancer immunotherapy during the unexploited immediate perioperative period10.1038/s41571-019-0319-9 ↗
4. Single-cell genomic approaches for developing the next generation of immunotherapies10.1038/s41591-019-0736-4 ↗
5. The market for chimeric antigen receptor T cell therapies10.1038/nrd.2017.266 ↗
6. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models10.1038/s41388-018-0187-2 ↗
7. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges10.1038/nrclinonc.2018.29 ↗
8. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
9. Cancer-related inflammation10.1038/nature07205 ↗
10. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment10.1126/science.1240527 ↗
11. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity10.1258/ebm.2011.011007 ↗
12. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication10.1111/j.1600-065X.2011.01007.x ↗
13. Cancer. Cancer immunotherapy is more than a numbers game10.1126/science.1133893 ↗
14. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression10.1016/j.ccr.2011.04.016 ↗
15. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm10.1038/ni.1937 ↗
16. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma10.4049/jimmunol.169.5.2756 ↗
17. Fatal attraction: tumors beckon regulatory T cells10.1038/nm0904-900 ↗
18. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses10.1158/0008-5472.CAN-04-0465 ↗
19. Tumor-induced immune dysfunctions caused by myeloid suppressor cells10.1097/00002371-200111000-00001 ↗
20. Engineering patient-specific cancer immunotherapies10.1038/s41551-019-0436-x ↗
21. Combining immunotherapy and targeted therapies in cancer treatment10.1038/nrc3237 ↗
22. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps10.1038/nrc3153 ↗
23. Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy10.1038/s41565-019-0485-z ↗
24. Smart cancer nanomedicine10.1038/s41565-019-0567-y ↗
25. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges10.1038/s41571-019-0308-z ↗
26. Enhancing cancer immunotherapy with nanomedicine10.1038/s41577-019-0269-6 ↗
27. Cancer nanomedicine for combination cancer immunotherapy10.1038/s41578-019-0108-1 ↗
28. Improving cancer immunotherapy through nanotechnology10.1038/s41568-019-0186-9 ↗
29. Lessons from immuno-oncology: a new era for cancer nanomedicine?10.1038/nrd.2017.34 ↗
30. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy10.1038/nnano.2017.69 ↗
31. Cancer nanomedicine for combination cancer immunotherapy10.1038/s41578-019-0108-1 ↗
32. Enhancing cancer immunotherapy with nanomedicine10.1038/s41577-019-0269-6 ↗
33. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy10.1002/adma.201803322 ↗
34. Nanomedicine and macroscale materials in immuno-oncology10.1039/C8CS00473K ↗
35. Harnessing designed nanoparticles: current strategies and future perspectives in cancer immunotherapy10.1016/j.nantod.2017.10.008 ↗
36. Combining nanomedicine and immunotherapy10.1021/acs.accounts.9b00148 ↗
37. Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells10.1038/s41416-020-0743-8 ↗
38. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment10.1038/s41423-019-0306-1 ↗
39. Monocyte recruitment during infection and inflammation10.1038/nri3070 ↗
40. Myeloid-derived suppressor cells coming of age10.1038/s41590-017-0022-x ↗
41. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected10.1172/JCI80005 ↗
42. Coordinated regulation of myeloid cells by tumours10.1038/nri3175 ↗
43. Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy10.1016/j.copbio.2019.01.010 ↗
44. Macrophages as regulators of tumour immunity and immunotherapy10.1038/s41577-019-0127-6 ↗
45. Tailoring nanomaterials for targeting tumor-associated macrophages10.1002/adma.201808303 ↗
46. Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for efficient Interleukin-12 cancer gene therapy
47. Implantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: postoperative immunotherapy10.1002/adma.201706719 ↗
48. Degradation-regulatable architectured implantable macroporous scaffold for the spatiotemporal modulation of immunosuppressive microenvironment and enhanced combination cancer immunotherapy10.1002/adfm.201804490 ↗
49. A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells10.7150/thno.21342 ↗
50. Regulation of myeloid development and function by colony stimulating factors10.1016/j.dci.2003.09.010 ↗
51. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells10.4049/jimmunol.1000901 ↗
52. Induction of myeloid-derived suppressor cells by tumor exosomes10.1002/ijc.24249 ↗
53. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells10.2353/ajpath.2010.090777 ↗
54. Plasticity of myeloid-derived suppressor cells in cancer10.1016/j.coi.2018.03.009 ↗
55. Histidine decarboxylase-expressing PMN-MDSC-derived TGF-β1 promotes the epithelial-mesenchymal transition of metastatic lung adenocarcinoma
56. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner10.1016/j.celrep.2015.08.077 ↗
57. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation10.1084/jem.20131916 ↗
58. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma10.1038/s41467-017-00530-7 ↗
59. Recent advances in myeloid-derived suppressor cell biology
60. The role of myeloid-derived suppressor cells (MDSC) in cancer progression10.3390/vaccines4040036 ↗
61. Suppression of T cells by myeloid-derived suppressor cells in cancer10.1016/j.humimm.2016.12.001 ↗
62. Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression10.1002/ijc.30538 ↗
63. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma10.18632/oncotarget.9270 ↗
64. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression10.1038/s41416-018-0333-1 ↗
65. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer10.3389/fimmu.2011.00029 ↗
66. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor10.1371/journal.pbio.1001162 ↗
67. Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species10.3109/08923973.2015.1059442 ↗
68. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways10.1002/ijc.28622 ↗
69. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells10.1084/jem.20101956 ↗
70. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes10.7554/eLife.17375 ↗
71. Myeloid-derived suppressor cells: linking inflammation and cancer10.4049/jimmunol.0802740 ↗
72. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease10.4049/jimmunol.174.2.636 ↗
73. Reversal of tumor-mediated immunosuppression10.1158/1078-0432.CCR-06-1924 ↗
74. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives10.1111/j.1600-065X.2008.00608.x ↗
75. Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell (MDSC)-mediated inhibition of T cell proliferation10.1002/eji.201747355 ↗
76. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer10.4049/jimmunol.1201449 ↗
77. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine10.1158/0008-5472.CAN-09-2587 ↗
78. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression10.1038/s41416-018-0333-1 ↗
79. Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer10.1164/rccm.201708-1707OC ↗
80. PD-L1(+)MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment10.1038/srep39296 ↗
81. Myeloid-derived suppressor cells as regulators of the immune system10.1038/nri2506 ↗
82. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors10.1093/jnci/djh301 ↗
83. Cancer immunotherapy comes of age10.1038/nature10673 ↗
84. CAR-T cells: the long and winding road to solid tumors10.1038/s41419-018-0278-6 ↗
85. Fundamental mechanisms of immune checkpoint blockade therapy10.1158/2159-8290.CD-18-0367 ↗
86. Programming CAR-T cells to kill cancer10.1038/s41551-018-0235-9 ↗
87. Immune-related adverse events with immune checkpoint blockade: a comprehensive review10.1016/j.ejca.2015.11.016 ↗
88. Improved survival with ipilimumab in patients with metastatic melanoma10.1056/NEJMoa1003466 ↗
89. Granulocytic myeloid-derived suppressor cells as negative regulators of anticancer immunity10.3389/fimmu.2020.01963 ↗
90. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications10.1053/j.seminoncol.2014.02.003 ↗
91. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion10.3389/fimmu.2020.01680 ↗
92. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer10.1007/s00262-013-1502-y ↗
93. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication10.4161/2162402X.2014.989764 ↗
94. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma10.4049/jimmunol.1200274 ↗
95. Expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors10.1158/2326-6066.CIR-18-0572 ↗
96. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas10.1158/2326-6066.CIR-15-0230 ↗
97. Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer10.1186/2051-1426-1-10 ↗
98. Myeloid-derived suppressor cells as a therapeutic target for cancer10.3390/cells9030561 ↗
99. Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis10.1002/jcp.26075 ↗
100. A clinical and biological perspective of human myeloid-derived suppressor cells in cancer10.1007/s00018-016-2278-y ↗